Please assess the completion status of the following clinical trial:

Trial Title: Symptomatic Therapy of Uncomplicated Lower Urinary Tract Infections in the Ambulatory Setting.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female~* Age between 18 and 70 years~* Written informed consent~* At least one typical symptom of acute, lower urinary tract infection out of dysuria, frequency, macrohaematuria, cloudy or smelly urine or self-diagnosed cystitis~* A urine dipstick test should be indicative of UTI by positive nitrite or leucocyturia~Exclusion Criteria~* Duration of UTI symptoms for more than 7 days before physician's visit~* Clinical signs of invasiveness such as fever (axillary body temperature \>38 degrees Celsius), costovertebral pain or tenderness, rigors, nausea or vomiting~* Known or suspicion of anatomical or functional abnormality of the urinary tract~* Vaginal symptoms: discharge, irritation~* Diabetes mellitus~* Immunosuppression (e.g. prednisone equivalent \>10mg per day for \>14 days, chemotherapy, radiotherapy, immunomodulators, HIV infection, neutropenia)~* Any other serious comorbidity as judged by the treating physician~* Bladder catheter in situ or during the past 30 days~* Pregnancy~* Recurrent urinary tract infection (more than 3 infections during the last 12 months)~* Antibiotic treatment during the last 4 weeks~* Hypersensitivity to one of the study medications~* Psychiatric illness or dementia~* Unable to communicate in German or French language~* Documented coagulopathy (including therapy with coumarine derivatives) or documented history of gastric or duodenal ulcer disease~* Documented renal insufficiency grade III or higher (calculated GFR \<60) or known congestive heart failure (NYHA III or higher)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- antibiotic (Type: ACTIVE_COMPARATOR): Norfloxacin for three days, followed by fosfomycin on day 4 if deemed necessary
- symptomatic (Type: EXPERIMENTAL): Diclofenac retard for three days, followed by fosfomycin on day 4 if deemed necessary

Based on this trial design, predict the completion outcome and termination type (if applicable).